{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:43:47Z","timestamp":1760985827414},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,15]]},"DOI":"10.2169\/internalmedicine.3200-19","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T22:02:58Z","timestamp":1566943378000},"page":"3577-3581","source":"Crossref","is-referenced-by-count":5,"title":["Steroid-responsive Nivolumab-induced Involuntary Movement with Anti-thyroid Antibodies"],"prefix":"10.2169","volume":"58","author":[{"given":"Yuta","family":"Maetani","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Nezu","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohisa","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Therapeutics, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22: 709-718, 2017.","DOI":"10.1634\/theoncologist.2016-0487"},{"key":"2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"2. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348: 56-61, 2015.","DOI":"10.1126\/science.aaa8172"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Suzuki S, Tanaka K, Yasuoka H, Fukuuchi Y, Kawakami Y, Kuwana M. Autoreactive T cells to the P3A+ isoform of AChR alpha subunit in myasthenia gravis. J Neuroimmunol 137: 177-186, 2003.","DOI":"10.1016\/S0165-5728(03)00078-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yoneda M, Fujii A, Ito A, Yokoyama H, Nakagawa H, Kuriyama M. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto&apos;s encephalopathy. J Neuroimmunol 185: 195-200, 2007.","DOI":"10.1016\/j.jneuroim.2007.01.018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kawamura R, Nagata E, Mukai M, et al. Acute cerebellar ataxia induced by nivolumab. Intern Med 56: 3357-3359, 2017.","DOI":"10.2169\/internalmedicine.8895-17"},{"key":"7","unstructured":"7. Mitoma H, Adhikari K, Aeschlimann D, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum 15: 213-232, 2016."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nanri K, Okuma M, Sato S, et al. Prevalence of autoantibodies and the efficacy of immunotherapy for autoimmune cerebellar ataxia. Intern Med 55: 449-454, 2016.","DOI":"10.2169\/internalmedicine.55.5156"},{"key":"9","unstructured":"9. Muramatsu T, Ikawa M, Yoneda M, et al. Pathophysiological decrease in the regional cerebral blood flow in Hashimoto&apos;s encephalopathy: a multiple-case SPECT study. Eur Neurol 72: 13-19, 2014."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Floyd M, El Osta B, Tang SC. First report of parkinsonism associated with indoximod, an immune-modulating agent. J Glob Oncol 4: 1-2, 2018.","DOI":"10.1200\/JGO.2016.007492"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3200-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T03:42:02Z","timestamp":1576899722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3200-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,15]]},"references-count":10,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3200-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,15]]}}}